Clinical Trial Update: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial [Phase 3]

View source ↗

Summary

A multicenter Phase 3 trial evaluating chemoradiotherapy plus anti-PD1 in recurrent nasopharyngeal carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: RECRUITING